Home » Topics » Respiratory, BioWorld Science

Respiratory, BioWorld Science
RSS

Forest's Infasurf earns approvable status

Aug. 23, 1996

FR-173657: Fujisawa's bradykinin B2 antagonist

Aug. 23, 1996

PAF antagonist Y-24180 enters phase III

Aug. 23, 1996

Proventil HFA given FDA approval

Aug. 23, 1996

Hoechst Marion Roussel launches Allegra on U.S. market

Aug. 23, 1996

Pseudostat enters phase II in CF patients

Aug. 16, 1996

LMA-Flexible introduced by Gensia

Aug. 16, 1996

SKB discloses drugs for IL-8-mediated disorders

Aug. 16, 1996

IL-8 role in emphysema and asthma suggested

Aug. 16, 1996

PDE IV inhibitors claimed by Euroceltique

Aug. 16, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.